APA (7th ed.) Citation

Lin, W., Huang, T., Chang, H., Chao, J., Chang, Y., Yang, C., . . . Lin, W. (2026). Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin–Angiotensin System Inhibitors Therapy. CTS: Clinical & Translational Science, 19(3), 1. https://doi.org/10.1111/cts.70509

Chicago Style (17th ed.) Citation

Lin, Wei‐Ren, Tzu‐Shan Huang, Ho‐Hsiang Chang, Jo‐Yen Chao, Yi‐Hsin Chang, Chen‐Yi Yang, Huang‐Tz Ou, and Wei‐Hung Lin. "Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin–Angiotensin System Inhibitors Therapy." CTS: Clinical & Translational Science 19, no. 3 (2026): 1. https://doi.org/10.1111/cts.70509.

MLA (9th ed.) Citation

Lin, Wei‐Ren, et al. "Kidney Effectiveness and Safety of Adding Spironolactone in Patients With Type 2 Diabetes Receiving Renin–Angiotensin System Inhibitors Therapy." CTS: Clinical & Translational Science, vol. 19, no. 3, 2026, p. 1, https://doi.org/10.1111/cts.70509.